A new cancer drug called trastuzumab deruxtecan, also known as Enhertu, has just been approved ... Imagine you're trying to deliver a package (a powerful cancer-killing drug) directly to a ...

AstraZeneca (NASDAQ:AZN) said on Monday that the late-stage trial for Enhertu, in combination with pertuzumab, showed significant improvement as a first line treatment of metastatic breast cancer ...

But the companies said Monday that the planned interim analysis showed the drug, Enhertu, led to a “highly statistically significant and clinically meaningful improvement in progression-free ...

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (trastuzumab deruxtecan) has been approved in the European Union as a treatment for adults with advanced breast ...

Amid these market pressures, the company's collaboration with Daiichi Sankyo was highlighted by the announcement of successful phase 3 trial results for ENHERTU, which positively impacts the ...

AstraZeneca and Daiichi Sankyo's Enhertu will become an option for hundreds more people with breast cancer in England and Wales, thanks to new guidance from NICE that will make it available via ...

Get Instant Summarized Text (Gist) Trastuzumab deruxtecan, known as Enhertu, has been approved in the UK for treating advanced HER2-positive cancers that are inoperable or have metastasized. This ...

A new cancer drug called trastuzumab deruxtecan, also known as Enhertu, has just been approved in the UK. This drug is designed to help adults with certain types of advanced cancer that cannot be ...